Pacira BioSciences, Inc.
PCRX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PCRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PCRX
Pacira BioSciences is a non-opioid pain therapy company commercializing EXPAREL, ZILRETTA, and iovera°, with a pipeline including gene therapy candidate PCRX-201 and a focus on expanding its commercial base and advancing clinical-stage assets.
Key risk: Integration and cost risks
BioSniper Score
Based on 6 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 3 catalysts for Pacira BioSciences, Inc..
Pacira BioSciences is a non-opioid pain therapy company commercializing EXPAREL, ZILRETTA, and iovera°, with a pipeline including gene therapy candidate PCRX-201 and a focus on expanding its commercial base and advancing clinical-stage assets.
- Record revenue of $701 million in 2024, at the high end of guided range [sec · filed 2025-04-29].
- Cash & equivalents of $205.9M, total revenue of $192.4M, net income of $4.7M, shareholders' equity of $693.1M, and total debt of $363.1M as of 2026-06-30 [sec].
- PCRX-201 received the first-ever Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for a gene therapy product candidate [sec · filed 2025-04-29].
- In July 2026, Pacira completed the divestiture of iovera°, a handheld cryoanalgesia device [sec_mda · as of 2026-08-04].
- A new $300 million share repurchase plan was authorized in April 2025, effective through December 31, 2026 [sec · filed 2025-04-29].
What works
- Pacira achieved record revenue of $701 million in 2024, indicating strong commercial execution [sec · filed 2025-04-29].
- PCRX-201 received the first-ever RMAT designation from the FDA, which may expedite its development and review [sec · filed 2025-04-29].
- The company secured CMS coverage and product-specific reimbursement codes for both EXPAREL and iovera°, improving market access [sec · filed 2025-04-29].
- Pacira maintains a disciplined capital allocation approach, including a $300 million share repurchase plan authorized through 2026 [sec · filed 2025-04-29].
What to weigh
- Pacira faces risks related to the successful integration of businesses and the potential for higher-than-expected costs or delays [sec · filed 2025-07-10].
- The company's financial performance is subject to global and U.S. economic conditions, including inflation and rising interest rates [sec · filed 2025-07-10].
- The success of EXPAREL, ZILRETTA, and iovera° depends on market acceptance and the size and growth of their potential markets [sec · filed 2025-07-10].
- Pacira's pipeline, including PCRX-201 and PCRX-2002, is still in clinical development and faces regulatory and commercial uncertainties [sec_mda · as of 2026-08-04].
From the filings
Quoted directly from source documents.
Record revenue in 2024
“We achieved record revenues of $701 million, the high end of our guided range.”
SEC filings · April 29, 2025
First-ever RMAT designation for a gene therapy product candidate
“We also won the FDA's first-ever RMAT designation”
SEC filings · April 29, 2025
Divestiture of iovera° in July 2026
“In July 2026, we completed the divestiture of iovera°, a handheld cryoanalgesia device that delivers immediate, long-a”
SEC MD&A · August 4, 2026
New $300 million share repurchase plan authorized in April 2025
“we replaced this with a new and increased authorization of $300 million in April 2025, which is authorized through December 31, 2026.”
SEC filings · April 29, 2025
Catalyst timeline
- 2026-12-31 · Phase2_Topline · pcrx-201 — Phase 2 Readout: pcrx-201 — Top-line results from the Phase 2 trial of PCRX-201 are expected, which will inform the program's further development.
- 2031-08-04 · Patent_Expiry · ZILRETTA — Patent/Exclusivity Expiry: ZILRETTA — Patent or exclusivity protection for ZILRETTA is set to expire, which could open the market to generic competition.
- 2044-07-02 · Patent_Expiry · EXPAREL — Patent/Exclusivity Expiry: EXPAREL — Patent or exclusivity protection for EXPAREL is set to expire, which could eventually affect market exclusivity.
Risks & what to watch (4)›
Key risks
- Integration and cost risks — Risk that businesses will not be integrated successfully, or that integration may be more costly than expected [sec · filed 2025-07-10].
- Market acceptance of products — Success depends on rate and degree of market acceptance of EXPAREL, ZILRETTA, and iovera° [sec · filed 2025-07-10].
- Economic conditions impact — Global and U.S. economic conditions, including inflation and rising interest rates, may affect the company's revenues and results [sec · filed 2025-07-10].
- Pipeline development uncertainty — Clinical-stage candidates like PCRX-201 and PCRX-2002 face regulatory and commercial risks [sec_mda · as of 2026-08-04].
What to watch
- Top-line Phase 2 data for PCRX-201 expected by end of 2026 [catalyst].
- Commercial performance of EXPAREL and ZILRETTA following the divestiture of iovera° [sec_mda · as of 2026-08-04].
- Progress of regulatory activities for EXPAREL and ZILRETTA, including sNDAs and MAAs [sec_mda · as of 2026-08-04].
- Execution of the $300 million share repurchase plan through December 2026 [sec · filed 2025-04-29].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 23, 2026 · How we verify sources →
Run Pacira BioSciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Pacira BioSciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 0.85 · 2% dilution
Lead: Approved
4 candidates
3 upcoming, next in ~123d
0 buys · 9 sells (180d)
Catalysts
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
238
Total value held
$936.6M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 6,735,343 | $152.2M |
| vanguard capital management llc | 3,568,098 | $80.6M |
| vanguard portfolio management llc | 2,501,286 | $56.5M |
| dimensional fund advisors lp | 2,060,597 | $46.6M |
| d. e. shaw & co., inc. | 1,982,724 | $44.8M |
| state street corp | 1,919,610 | $43.4M |
| renaissance technologies llc | 1,825,501 | $41.3M |
| goldman sachs group inc | 1,569,916 | $35.5M |
| morgan stanley | 1,392,548 | $31.5M |
| geode capital management, llc | 1,143,820 | $25.9M |
Showing top 10 of 238 institutional holders of Pacira BioSciences, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 30.0%
- Days to cover
- 9.8
- Shares short
- 8,059,032
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PCRX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Pacira BioSciences, Inc.?
Pacira BioSciences is a non-opioid pain therapy company commercializing EXPAREL, ZILRETTA, and iovera°, with a pipeline including gene therapy candidate PCRX-201 and a focus on expanding its commercial base and advancing clinical-stage assets.
What is Pacira BioSciences, Inc.'s lead drug candidate?
Pacira BioSciences, Inc.'s most advanced tracked candidate is EXPAREL (Approved) for Postsurgical pain management; local analgesia via infiltration in patients aged six years and older and regional analgesia via interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and adductor canal block in adults..
What is Pacira BioSciences, Inc.'s next catalyst?
Pacira BioSciences, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: pcrx-201" — expected December 31, 2026.
Who is the CEO of Pacira BioSciences, Inc.?
Mr. Frank D. Lee is the chief executive officer of Pacira BioSciences, Inc. (PCRX).
Where is Pacira BioSciences, Inc. headquartered?
Pacira BioSciences, Inc. (PCRX) is headquartered in Brisbane, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.